Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: A randomized clinical trial

Journal of Infectious Diseases

Volumn 205, Issue 5, 2012, Pages 703-712

  El Sahly, Hana M ^a,b   Davis, Charles ^c   Kotloff, Karen ^c   Meier, Jeffery ^d   Winokur, Patricia L ^d   Wald, Anna ^e   Johnston, Christine ^e   George, Sarah L ^f,g   Brady, Rebecca C ^h   Lehmann, Corinne ^h   Stokes Riner, Abbie ⁱ   Keitel, Wendy A ^a,b  

^a Department of Molecular Virology and Microbiology ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN FUNCTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; CD4 LYMPHOCYTE COUNT; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; HIV INFECTIONS; HIV-1; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; TIME FACTORS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84856919430     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir837     Document Type: Article

References (25)

1. http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/ us-overview.htm. Accessed 29 October 2010.
2. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281:901-7. (Pubitemid 29124633)
3. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-6. (Pubitemid 32116562)
4. Neuzil KM, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003; 34: 304-7. (Pubitemid 37377365)
5. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990; 98:33-7. (Pubitemid 20223662)
6. Cohen JP, Macauley C. Susceptibility to influenza A in HIV-positive patients. JAMA 1989; 261:245.
7. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1-60.
8. Perez CM, Dominguez MI, Ceballos ME, et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. AIDS 2010; 24:2867-9.
9. Archer B, Cohen C, Naidoo D, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009; 14:19369.
10. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIVinfected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:147-9.
11. Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-92.
12. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
13. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-23.
14. Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24:F31-5.
15. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52:122-7.
16. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77.
17. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-56.
18. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
19. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001; 65:644-8. (Pubitemid 33135090)
20. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83. (Pubitemid 19189001)
21. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIVinfected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011; 6:e16496.
22. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
23. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7. (Pubitemid 43765184)
24. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10.
25. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD41 lymphocytes. AIDS 1994; 8:469-76. (Pubitemid 24102296)